The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -28,753,844 |
| Depreciation and amortization expense | 363,085 |
| Change in value of warrant liabilities | -1,424,603 |
| Commitment shares issued for equity line of credit | 568,235 |
| Common shares issuance for services | 595,841 |
| Stock-based compensation | 4,265,957 |
| Amortization of non-cash prepaids | -1,037,631 |
| Accounts payable | 8,274,316 |
| Accrued expenses | 893,992 |
| Accrued payroll and payroll taxes | -59,186 |
| Amortization of debt discounts issuance and warrants | 0 |
| Shares issued for services | 0 |
| Shares issued for interest expense | 0 |
| Accrued interest on convertible notes | 0 |
| Net cash used in operating activities | -14,238,576 |
| Patent license acquisition | 466,423 |
| Net cash used in investing activities | -466,423 |
| Prepaid warrants (net of fees) | 530,162 |
| Common stock issuance (net of fees) | 7,858,140 |
| Sale of preferred stock | 1,053,000 |
| Short-term borrowings | 0 |
| Short-term loan repayments | 0 |
| Initial public offering (net of fees) | 0 |
| Net proceeds from conversion of debt a, b, c, d, e & f | 0 |
| Net cash provided by financing activities | 9,441,302 |
| Net change in cash | -5,263,697 |
| Cash beginning of period | 5,533,527 |
| Cash end of period | 269,830 |
OS Therapies Inc (OSTX)
OS Therapies Inc (OSTX)